MNMD
Mind Medicine (MindMed) Inc.
$10.68
-$0.20(-1.84%)
35
Overall
40
Value
30
Tech
--
Quality
Market Cap
$1.17B
Volume
1.73M
52W Range
$4.70 - $14.43
Target Price
$25.64
Company Overview
| Mkt Cap | $1.17B | Price | $10.68 |
| Volume | 1.73M | Change | -1.84% |
| P/E Ratio | -10.8 | Open | $10.87 |
| Revenue | -- | Prev Close | $10.88 |
| Net Income | $-108.7M | 52W Range | $4.70 - $14.43 |
| Div Yield | N/A | Target | $25.64 |
| Overall | 35 | Value | 40 |
| Quality | -- | Technical | 30 |
No chart data available
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Latest News
H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)
TipRanks Auto-Generated Intelligence Newsdesk•13 days ago
MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations
TipRanks Canadian Auto-Generated Newsdesk•20 days ago
MindMed Issues Inducement Grants to New Employees
TipRanks Canadian Auto-Generated Newsdesk•20 days ago
Mind Medicine Completes Successful Public Offering
TipRanks Auto-Generated Newsdesk•23 days ago
Mind Medicine (MNMD) Receives a Buy from Oppenheimer
TipRanks Auto-Generated Intelligence Newsdesk•23 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MNMD | $10.68 | -1.8% | 1.73M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mind Medicine (MindMed) Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW